Research summary, original research, 2017

A Multicenter Survey of Endovascular Theatre Equipment and Radiation Exposure in France during Iliac Procedures

Maurel B, Hertault A, Salomon du Mont L, Cazaban S, Rinckenbach S. Annals of vascular surgery. 2017

Read the original paper

In plain language

Among French vascular surgeons performing iliac procedures, patient dose area product rose from 2012 to 2015 alongside more hybrid rooms and more complex procedures, despite training. Staff dose was not measured, but patient dose indicates scatter exposure for the fluoroscopy team.

At a glance

Type of study
Original research, Prospective cohort study
Who was studied
Vascular surgeons, Patients
Size
n = 959 procedures
Where
France
Summary based on
the abstract

What it found

  • Mean dose area product rose significantly between 2012 and 2015 despite radiation safety training.

    Key figures: 14.2 ± 18.9 Gy cm2 in 2012 vs 21.5 ± 37.6 Gy cm2 in 2015 (P < 0.01)

  • Hybrid rooms, body mass index (BMI) over 25, more than one stent and crossover technique were associated with higher dose-area product (DAP).

  • Fluoroscopy time did not change significantly.

    Key figures: 4.8 ± 5.5 min vs 5.2 ± 5.9 min (nonsignificant)

  • Use of hybrid rooms, mobile flat-panel detectors and dedicated radiology tables increased over the 3 years.

    Key figures: hybrid rooms 1.5% vs 14.7%; flat-panel 1.1% vs 5.9%; dedicated tables 37.2% vs 51.2%

  • Procedure complexity increased over time, including more multi-stent procedures.

    Key figures: 32.3% vs 41%, P < 0.01

Limits to keep in mind

Observational comparison of two self-selected cohorts of training attendees with exclusions and different surgeon numbers; only patient dose metrics (DAP) were measured, not staff dose, and confounding by complexity and equipment is likely.

How this summary was made

ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.